Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin

abstract

  • Veltuzumab appeared safe and active at all tested doses, encouraging further study, including dose levels less than those typically used with rituximab.

publication date

  • July 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.19.9117

PubMed ID

  • 19451441

Additional Document Info

start page

  • 3346

end page

  • 53

volume

  • 27

number

  • 20